Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upgraded the stock, citing improved earnings outlooks and strong market demand. The company plans to expand further with AI healthcare initiatives and an acquisition, though risks like China divestiture and margin pressures remain. Investors should weigh these factors when considering Revvity's future potential.
Revvity Inc trades at USD 157.30 on Pluang as of Oct 06, 2026 05:11 WIB, showing a 3.81% gain in one day. The stock has a market cap of $16.26 billion and typical hold time is 12 days. This trading activity complements the recent positive outlook and upgrades noted in the article.
